Front Row Advisors’s iShares iBonds Dec 2027 Term Corporate ETF IBDS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$190K Buy
7,850
+2,000
+34% +$48.4K 0.05% 124
2026
Q1
$142K Buy
5,850
+1,650
+39% +$40.1K 0.05% 136
2025
Q4
$102K Hold
4,200
0.03% 159
2025
Q3
$102K Buy
4,200
+3,000
+250% +$72.8K 0.03% 157
2025
Q2
$29.1K Hold
1,200
0.01% 257
2025
Q1
$29K Hold
1,200
0.01% 261
2024
Q4
$28.8K Buy
+1,200
New +$28.9K 0.01% 259

Other funds holding IBDS

Front Row Advisors's IBDS Position: Q2 2026 in Review

Front Row Advisors increased its iShares iBonds Dec 2027 Term Corporate ETF (IBDS) stake by 34% in Q2 2026, buying an estimated $48.4K and bringing the position to 7,850 shares worth $190K. The position accounts for 0.05% of the portfolio, ranked #124.

Front Row Advisors first reported a position in IBDS in Q4 2024 and has held it in 7 quarters since. 416 funds tracked by Wall St. Rank hold IBDS as of Q2 2026.

  • Front Row Advisors held 7,850 shares of iShares iBonds Dec 2027 Term Corporate ETF worth $190K as of Q2 2026.
  • Front Row Advisors bought 2,000 iShares iBonds Dec 2027 Term Corporate ETF shares in Q2 2026, an estimated $48.4K.
  • iShares iBonds Dec 2027 Term Corporate ETF made up 0.05% of Front Row Advisors's portfolio in Q2 2026, its #124 holding.
  • Front Row Advisors first reported a position in iShares iBonds Dec 2027 Term Corporate ETF in Q4 2024 and has held it in 7 quarters since.
  • 416 funds tracked by Wall St. Rank held iShares iBonds Dec 2027 Term Corporate ETF as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.